Vaxcyte, Inc. — Form 8-K Summary
Reporting context: The 8-K reports concurrent equity and convertible-debt offerings agreed to on October 6, 2026 and closed on October 9, 2026. It does not report quarterly or annual operating results.
Financing and key financial terms
- Equity offering: Vaxcyte sold 7,412,500 common shares at $64.00 per share and pre-funded warrants for 400,000 shares at $63.999 each. Underwriters exercised their option in full for an additional 1,171,875 shares. Net proceeds were approximately $544.3 million, after underwriting discounts, commissions, and estimated expenses.
- Convertible notes: Vaxcyte issued $575 million aggregate principal amount of 1.50% senior unsecured convertible notes due October 15, 2032. The $75 million debt over-allotment option was exercised in full. Net proceeds were approximately $558.7 million.
- Combined net proceeds: Approximately $1.103 billion from the two offerings. The filing does not specify intended uses of proceeds.
- Interest and conversion: Notes pay interest semi-annually, beginning April 15, 2027. The initial conversion rate is 11.1607 shares per $1,000 principal amount, equivalent to an approximate $89.60 conversion price. Vaxcyte may settle conversions in cash, shares, or a combination.
- Other financial metrics: The filing provides no revenue, profit, cash-flow, margin, cash-balance, or liquidity figures and no comparable-period results.
Material changes and obligations
- The offerings add substantial cash proceeds while creating $575 million of unsecured debt and potential dilution from conversion of the notes and exercise of the pre-funded warrants and any related share issuance.
- Interest accrues at 1.50% annually; principal is due at maturity unless the notes are earlier repurchased, redeemed, or converted.
- Before July 15, 2032, conversion is permitted only upon specified events; thereafter, holders may convert at their election until shortly before maturity.
- Vaxcyte may provisionally redeem notes from October 22, 2029 if specified stock-price conditions are met, and may redeem all remaining notes if less than 10% of the originally issued principal remains outstanding. Holders may require repurchase following specified fundamental changes.
Risks and items to verify
- Review the indenture and offering exhibits for full conversion, redemption, repurchase, default, and adjustment provisions.
- Verify the final share and warrant count, dilution assumptions, and treatment of the notes in future capital and liquidity disclosures.
- Confirm management’s intended use of the approximately $1.103 billion in net proceeds; this 8-K does not state it.
- Assess future interest and repayment obligations and the conditions that could trigger conversion, redemption, repurchase, or default.